Cargando…

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease

BACKGROUND AND AIMS: Non‐O blood type (BT) is a risk factor for thromboses, which has been attributed to its effects on von Willebrand factor (VWF)/factor VIII (FVIII) levels. Although high VWF/FVIII may be risk factors for portal vein thrombosis (PVT) in patients with advanced chronic liver disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheiner, Bernhard, Northup, Patrick G., Gruber, Anselm B., Semmler, Georg, Leitner, Gerda, Quehenberger, Peter, Thaler, Johannes, Ay, Cihan, Trauner, Michael, Reiberger, Thomas, Lisman, Ton, Mandorfer, Mattias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Genetics and Rare Liver Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317432/ https://www.ncbi.nlm.nih.gov/pubmed/32052552 http://dx.doi.org/10.1111/liv.14404

Ejemplares similares

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension
por: Paternostro, Rafael, et al.
Publicado: (2020)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

Non‐invasive diagnosis of cirrhosis and long‐term disease monitoring by transient elastography in patients with Wilson disease
por: Paternostro, Rafael, et al.
Publicado: (2020)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Alpha‐fetoprotein‐adjusted‐to‐HCC‐size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma
por: Meischl, Tobias, et al.
Publicado: (2021)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19
por: Hartl, Lukas, et al.
Publicado: (2021)

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease
por: Beer, Lucian, et al.
Publicado: (2020)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2019)

Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
por: Raeven, Pierre, et al.
Publicado: (2020)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata
por: Hartl, Lukas, et al.
Publicado: (2022)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Portal hypertensive gastropathy is associated with iron deficiency anemia
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Adult Living Donor Liver Transplantation for Patients With Portal Vein Thrombosis: A Single-center Experience
por: Miura, Kohei, et al.
Publicado: (2018)

Low Titers of Antidonor ABO Antibodies After ABO-Incompatible Living Donor Liver Transplantation: A Long-Term Follow-Up Study
por: Ueda, Daisuke, et al.
Publicado: (2018)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2022)

Effect of common genetic variants on the risk of cirrhosis in non‐alcoholic fatty liver disease during 20 years of follow‐up
por: Holmer, Magnus, et al.
Publicado: (2022)

DCD Liver Grafts Can Safely Be Used for Recipients With Grade I–II Portal Vein Thrombosis: A Multicenter Analysis
por: Mercado, Lydia A., et al.
Publicado: (2022)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Acute Antibody-mediated Rejection Coexisting With T Cell–mediated Rejection in Pediatric ABO-incompatible Transplantation
por: Yanagi, Yusuke, et al.
Publicado: (2022)

Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence
por: Dendy, Meaghan S., et al.
Publicado: (2017)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression
por: Jachs, Mathias, et al.
Publicado: (2022)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fpu80hcnq1q8tdtmojohs4ra2t